Bharat Parenterals Ltd (BPLPHARMA) is currently trading at 1,655.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bharat Parenterals Limited is an integrated pharmaceutical platform headquartered in Vadodara that manufactures finished dosages and parenterals, operating three main entities: BPL standalone (export-led FDFs), Innoxel Lifesciences (US/EU-facing CDMO and complex generics) and Varenyam Healthcare and Varenyam Bio (institutional branded sales and emerging-regulated manufacturing). Consolidated Q1 FY27 revenue was ₹93.7 Cr, down 19% YoY mainly due to tranche timing of a prior ₹210 Cr institutional order; however gross margin improved sharply to 50.6%, keeping gross profit flat at ₹47.4 Cr and highlighting revenue mix shifts and margin resilience at Bharat Parenterals Limited. Innoxel is the strategic high-growth engine: Q1 revenue rose 165% YoY to ₹21.4 Cr, cumulative licensing revenue ₹72.4 Cr and 23 deals signed in FY26; operating losses at Innoxel are currently dragging consolidated PAT, but management expects Innoxel to reach quarterly EBITDA break-even as CMO supplies commercialize. Varenyam Healthcare is scaling rapidly in India’s institutional channel with Q1 revenue ₹25.1 Cr (+52% YoY), a 211-strong MR force expanding to 250 and flagship brands like Sugmadex driving institutional penetration; Varenyam Bio is pre-revenue but progressing a sizable EU-GMP project with commissioning target Sept 2027.

Over the past 52 weeks, Bharat Parenterals Ltd has traded between a low of ₹880.25 and a high of ₹2,274.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bharat Parenterals Ltd has a market capitalization of approximately 1,145.96. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bharat Parenterals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -38.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,145.96 Cr, Bharat Parenterals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bharat Parenterals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bharat Parenterals Ltd is -38.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved a preferential allotment of 9,12,759 equity shares at ₹1,522.85 per share to raise about ₹139 crore, subject to shareholder approval.